Tomas Bjorklund

We’re proud to announce that @AstellasUS has exercised its $15M option to license a Dyno AI-designed adeno-associated virus (AAV) capsid for skeletal muscle-targeted gene delivery, building on our 2021 collaboration agreement. This marks our second capsid license to a pharmaceutical partner, and it makes Dyno the first company to license AI-designed AAV capsids for both central nervous system (CNS) and muscle gene therapies. This milestone reflects years of platform development, validating our conviction that AI can solve the gene delivery challenge for therapeutic developers and ultimately create many good treatment options for patients. Learn more: businesswire.com/news/home/2026…

🎉🧬We’re thrilled to announce a new strategic partnership with @Roche to advance next-generation #AAV gene therapies for neurological diseases. More on this partnership milestone: tinyurl.com/dynoroche24

We are #hiring! This exciting research line applies cutting-edge spatial sequencing to a unique sample set of post-mortem Alzheimer's brains. #SfN24 fens.org/careers/job-ma…

We're excited to announce our collaboration with @nvidia. Working with the world’s leading computing company and building within NVIDIA's BioNeMo will accelerate Dyno's AI-powered sequence design and bring us all closer to helping patients with transformative new medicines.

New research from @Bjorklund lead by @UCPH_DanStem postdoc Patrick Aldrin-Kirk: A novel two-factor monosynaptic TRIO tracing method to assess circuit integration of hESC-derived dopamine transplants, bit.ly/3G022sO. @ParmarLab @lunduniversity @martinperaJAX @ISSCR

New research from @Bjorklund @ParmarLab & @lunduniversity colleagues presents a novel 2-factor monosynaptic TRIO tracing method for assessment of circuit integration of hESC-derived dopamine transplants; AAV-capsid MNM008 for accurate monosynaptic tracing cell.com/stem-cell-repo…

Dyno announces our partnership with Astellas, valued at up to $1.6 billion, for developing next-gen AAV gene therapy vectors for skeletal and cardiac muscle diseases. bit.ly/3xHDP7j

Dyno Therapeutics Closes $100 Million Series A Financing Led by Andreessen Horowitz to Accelerate AI‑powered Gene Therapy Platform. dynotx.com/dyno-closes-10…

We're excited to kick-off our collaboration with @Roche and @spark_tx!

Dyno Therapeutics Enters Collaboration and License Agreement with Roche to Develop Next-Generation AAV Gene Therapy Vectors for CNS Diseases and Liver-Directed Therapies Press release here: dynotx.com/news/press-rel…

Our collaboration combines Dyno’s AI-powered AAV vector engineering with Roche and Spark Therapeutics’ leading-edge #genetherapy capabilities. Read more about it: dynotx.com/news/press-rel…

We are honored and excited to receive the @Xconomy National StartUp of the Year Award on behalf of the Dyno team, working hard to transform #genetherapy. Congratulations to all finalists and to everyone making an impact in the #lifesciences community. #XconAwards

Congratulations to Dyno Therapeutics, the #XconAwards Startup of the Year. Dyno is working to accelerate the design of optimized gene therapies. Learn more about them and the other category finalists: youtu.be/VkHpofU15_M @Dyno_Tx

New Gene Therapy Delivery Method May Open BRAVE New World in Parkinson’s Research parkinsonsnewstoday.com/2019/12/18/new…

Cool! Directed evolution of AAV to achieve specificity--potential translational value clear! pnas.org/content/early/…

Congrats to Dyno SAB member and scientific cofounder Tomas Bjorklund for publication of the @PNASNews paper on #AAV capsid engineering using synthetic peptide insertions. A beautiful work! pnas.org/content/early/…